# Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

> **NCT05068427** · PHASE2 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Envafolimab

## Key facts

- **NCT ID:** NCT05068427
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-23
- **Primary completion:** 2023-02-23
- **Final completion:** 2024-05-16
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068427, "Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05068427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*